Metrics as of 10/15/2026, 02:16 PM (Berlin time), refresh in progress.
Tarsus Pharmaceuticals Stock
Tarsus Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Bobak R. Azamian
- Employees
- 370
- Market cap
- $3.4 B
- IPO
- 16/10/2020
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm within the Healthcare sector that is dedicated to advancing and commercializing innovative therapies. The company focuses primarily on ocular conditions. Its leading investigational drug, TP-03, which is currently in Phase III trials, is being…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Tarsus Pharmaceuticals stock: price history
1D
+2.1%
1W
-1.8%
1M
-9.6%
6M
+0.7%
YTD
-11.7%
1Y
+3.5%
2Y
+98.2%
5Y
+153.5%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~4% stronger price swings than usual
Ask the agents about Tarsus Pharmaceuticals
Analyst assessment of Tarsus Pharmaceuticals
PRICE TARGET LOW
US$89.00
CONSENSUS
US$103.00
MEDIAN
US$102.50
PRICE TARGET HIGH
US$116.00
1
STRONG BUY
8
BUY
1
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 08/09/2026
Tarsus Pharmaceuticals stock metrics
P/E
-66.32
P/B
9.05
EV/EBITDA
-92.6
RETURN ON EQUITY
-5.4%
NET MARGIN
-10.7%
DEBT/EQUITY
0.26
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.3%
FLOAT SHARES
44,108,056
AVG. DAILY VOLUME (30D)
890,267
Insider transactions (SEC)
LINK WILLIAM J PHD
LINK WILLIAM J PHD
LINK WILLIAM J PHD
LINK WILLIAM J PHD
YARNO WENDY L
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +2.1%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Tarsus Pharmaceuticals stock
What does Tarsus Pharmaceuticals do?
Tarsus Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Bobak R. Azamian, the company employs around 370 people.
The IPO was on 16/10/2020; the stock trades on NASDAQ under the ticker TARS.
What do analysts say about Tarsus Pharmaceuticals stock?
10 analysts rate the stock, the consensus is Buy (as of 08/09/2026).
The average price target is US$103.00, ranging from US$89.00 to US$116.00, with a median of US$102.50.
This is an external assessment, not a statement by Market Jury.
When does Tarsus Pharmaceuticals report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 4% stronger than usual.
Does Tarsus Pharmaceuticals pay a dividend?
No, Tarsus Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Tarsus Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Tarsus Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Tarsus Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.